Company / Accounts Receivable
PULSE BIOSCIENCES, INC. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$274.0K
FY2025
5-year range
$0 / $274.0K
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#138 of 138
Health Care
What the data says
Among 138 Health Care companies, PULSE BIOSCIENCES, INC. is in the bottom 0% for accounts receivable. Improved from $0 to $274,000 over the past 3 years.
Based on SEC 10-K filings.
$274,000 in FY2025.
Improved from $0 to $274,000 over the past 3 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 138This company $274.0K Sector average $1.3B
▼
-100.0% below sector average
Key checks
Key Insights
- Ranks #138 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $274.0K | - |
| FY2024 | $0 | - |
| FY2023 | - | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $61.0K | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026